Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat

Michael Kyriakides, Rhiannon N. Hardwick, Zhaosheng Jin, Michael J. Goedken, Elaine Holmes, Nathan J Cherrington, Muireann Coen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Adverse drug reactions (ADRs) represent a significant clinical challenge with respect to patient morbidity and mortality. We investigated the hepatotoxicity and systems level metabolic phenotype of methotrexate (MTX) in the context of a prevalent liver disease; non-alcoholic steatohepatitis (NASH). A nuclear magnetic resonance spectroscopic-based metabonomic approach was employed to analyze the metabolic consequences of MTX (0, 10, 40, and 100 mg/kg) in the urine and liver of healthy rats (control diet) and in a model of NASH (methionine-choline deficient diet). Histopathological analysis confirmed baseline (0 mg/kg) liver necrosis, liver inflammation, and lipid accumulation in the NASH model. Administration of MTX (40 and 100 mg/kg) led to liver necrosis in the control cohort, whereas the NASH cohort also displayed biliary hyperplasia and liver fibrosis (100 mg/kg), providing evidence of the synergistic effect of MTX and NASH. The complementary hepatic and urinary metabolic phenotypes of the NASH model, at baseline, revealed perturbation of multiple metabolites associated with oxidative and energetic stress, and folate homeostasis. Administration of MTX in both diet cohorts showed dose-dependent metabolic consequences affecting gut microbial, energy, nucleobase, nucleoside, and folate metabolism. Furthermore, a unique panel of metabolic changes reflective of the synergistic effect of MTX and NASH was identified, including the elevation of hepatic phenylalanine, urocanate, acetate, and both urinary and hepatic formiminoglutamic acid. This systems level metabonomic analysis of the hepatotoxicity of MTX in the context of NASH provided novel mechanistic insight of potential wider clinical relevance for further understanding the role of liver pathology as a risk factor for ADRs.

Original languageEnglish (US)
Pages (from-to)105-116
Number of pages12
JournalToxicological Sciences
Volume142
Issue number1
DOIs
StatePublished - Nov 1 2014

Fingerprint

Fatty Liver
Methotrexate
Liver
Rats
Phenotype
Nutrition
Metabolomics
Folic Acid
Diet
Drug-Related Side Effects and Adverse Reactions
Formiminoglutamic Acid
Rat control
Necrosis
Pathology
Metabolites
Choline
Phenylalanine
Nucleosides
Metabolism
Pharmaceutical Preparations

Keywords

  • liver toxicity
  • metabonomics
  • methionine-choline deficient diet
  • methotrexate
  • non-alcoholic steatohepatitis
  • nuclear magnetic resonance spectroscopy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat. / Kyriakides, Michael; Hardwick, Rhiannon N.; Jin, Zhaosheng; Goedken, Michael J.; Holmes, Elaine; Cherrington, Nathan J; Coen, Muireann.

In: Toxicological Sciences, Vol. 142, No. 1, 01.11.2014, p. 105-116.

Research output: Contribution to journalArticle

Kyriakides, Michael ; Hardwick, Rhiannon N. ; Jin, Zhaosheng ; Goedken, Michael J. ; Holmes, Elaine ; Cherrington, Nathan J ; Coen, Muireann. / Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat. In: Toxicological Sciences. 2014 ; Vol. 142, No. 1. pp. 105-116.
@article{9df3c02cc7134e988a0c443e234890e4,
title = "Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat",
abstract = "Adverse drug reactions (ADRs) represent a significant clinical challenge with respect to patient morbidity and mortality. We investigated the hepatotoxicity and systems level metabolic phenotype of methotrexate (MTX) in the context of a prevalent liver disease; non-alcoholic steatohepatitis (NASH). A nuclear magnetic resonance spectroscopic-based metabonomic approach was employed to analyze the metabolic consequences of MTX (0, 10, 40, and 100 mg/kg) in the urine and liver of healthy rats (control diet) and in a model of NASH (methionine-choline deficient diet). Histopathological analysis confirmed baseline (0 mg/kg) liver necrosis, liver inflammation, and lipid accumulation in the NASH model. Administration of MTX (40 and 100 mg/kg) led to liver necrosis in the control cohort, whereas the NASH cohort also displayed biliary hyperplasia and liver fibrosis (100 mg/kg), providing evidence of the synergistic effect of MTX and NASH. The complementary hepatic and urinary metabolic phenotypes of the NASH model, at baseline, revealed perturbation of multiple metabolites associated with oxidative and energetic stress, and folate homeostasis. Administration of MTX in both diet cohorts showed dose-dependent metabolic consequences affecting gut microbial, energy, nucleobase, nucleoside, and folate metabolism. Furthermore, a unique panel of metabolic changes reflective of the synergistic effect of MTX and NASH was identified, including the elevation of hepatic phenylalanine, urocanate, acetate, and both urinary and hepatic formiminoglutamic acid. This systems level metabonomic analysis of the hepatotoxicity of MTX in the context of NASH provided novel mechanistic insight of potential wider clinical relevance for further understanding the role of liver pathology as a risk factor for ADRs.",
keywords = "liver toxicity, metabonomics, methionine-choline deficient diet, methotrexate, non-alcoholic steatohepatitis, nuclear magnetic resonance spectroscopy",
author = "Michael Kyriakides and Hardwick, {Rhiannon N.} and Zhaosheng Jin and Goedken, {Michael J.} and Elaine Holmes and Cherrington, {Nathan J} and Muireann Coen",
year = "2014",
month = "11",
day = "1",
doi = "10.1093/toxsci/kfu160",
language = "English (US)",
volume = "142",
pages = "105--116",
journal = "Toxicological Sciences",
issn = "1096-6080",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat

AU - Kyriakides, Michael

AU - Hardwick, Rhiannon N.

AU - Jin, Zhaosheng

AU - Goedken, Michael J.

AU - Holmes, Elaine

AU - Cherrington, Nathan J

AU - Coen, Muireann

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Adverse drug reactions (ADRs) represent a significant clinical challenge with respect to patient morbidity and mortality. We investigated the hepatotoxicity and systems level metabolic phenotype of methotrexate (MTX) in the context of a prevalent liver disease; non-alcoholic steatohepatitis (NASH). A nuclear magnetic resonance spectroscopic-based metabonomic approach was employed to analyze the metabolic consequences of MTX (0, 10, 40, and 100 mg/kg) in the urine and liver of healthy rats (control diet) and in a model of NASH (methionine-choline deficient diet). Histopathological analysis confirmed baseline (0 mg/kg) liver necrosis, liver inflammation, and lipid accumulation in the NASH model. Administration of MTX (40 and 100 mg/kg) led to liver necrosis in the control cohort, whereas the NASH cohort also displayed biliary hyperplasia and liver fibrosis (100 mg/kg), providing evidence of the synergistic effect of MTX and NASH. The complementary hepatic and urinary metabolic phenotypes of the NASH model, at baseline, revealed perturbation of multiple metabolites associated with oxidative and energetic stress, and folate homeostasis. Administration of MTX in both diet cohorts showed dose-dependent metabolic consequences affecting gut microbial, energy, nucleobase, nucleoside, and folate metabolism. Furthermore, a unique panel of metabolic changes reflective of the synergistic effect of MTX and NASH was identified, including the elevation of hepatic phenylalanine, urocanate, acetate, and both urinary and hepatic formiminoglutamic acid. This systems level metabonomic analysis of the hepatotoxicity of MTX in the context of NASH provided novel mechanistic insight of potential wider clinical relevance for further understanding the role of liver pathology as a risk factor for ADRs.

AB - Adverse drug reactions (ADRs) represent a significant clinical challenge with respect to patient morbidity and mortality. We investigated the hepatotoxicity and systems level metabolic phenotype of methotrexate (MTX) in the context of a prevalent liver disease; non-alcoholic steatohepatitis (NASH). A nuclear magnetic resonance spectroscopic-based metabonomic approach was employed to analyze the metabolic consequences of MTX (0, 10, 40, and 100 mg/kg) in the urine and liver of healthy rats (control diet) and in a model of NASH (methionine-choline deficient diet). Histopathological analysis confirmed baseline (0 mg/kg) liver necrosis, liver inflammation, and lipid accumulation in the NASH model. Administration of MTX (40 and 100 mg/kg) led to liver necrosis in the control cohort, whereas the NASH cohort also displayed biliary hyperplasia and liver fibrosis (100 mg/kg), providing evidence of the synergistic effect of MTX and NASH. The complementary hepatic and urinary metabolic phenotypes of the NASH model, at baseline, revealed perturbation of multiple metabolites associated with oxidative and energetic stress, and folate homeostasis. Administration of MTX in both diet cohorts showed dose-dependent metabolic consequences affecting gut microbial, energy, nucleobase, nucleoside, and folate metabolism. Furthermore, a unique panel of metabolic changes reflective of the synergistic effect of MTX and NASH was identified, including the elevation of hepatic phenylalanine, urocanate, acetate, and both urinary and hepatic formiminoglutamic acid. This systems level metabonomic analysis of the hepatotoxicity of MTX in the context of NASH provided novel mechanistic insight of potential wider clinical relevance for further understanding the role of liver pathology as a risk factor for ADRs.

KW - liver toxicity

KW - metabonomics

KW - methionine-choline deficient diet

KW - methotrexate

KW - non-alcoholic steatohepatitis

KW - nuclear magnetic resonance spectroscopy

UR - http://www.scopus.com/inward/record.url?scp=84937580277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937580277&partnerID=8YFLogxK

U2 - 10.1093/toxsci/kfu160

DO - 10.1093/toxsci/kfu160

M3 - Article

VL - 142

SP - 105

EP - 116

JO - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 1

ER -